HUTCHMED (China) Limited (AIM: HCM)
London
· Delayed Price · Currency is GBP · Price in GBX
292.00
-8.00 (-2.67%)
Oct 11, 2024, 4:35 PM GMT+1
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $305.68M USD in the half year ending June 30, 2024, with 51.29% growth. This brings the company's revenue in the last twelve months to $610.81M, down -19.34% year-over-year. In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth.
Revenue (ttm)
$610.81M
Revenue Growth
-19.34%
P/S Ratio
5.16
Revenue / Employee
$307.25K
Employees
1,988
Market Cap
2.50B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHUTCHMED (China) News
- 11 days ago - HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2 - GuruFocus
- 19 days ago - HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - GlobeNewsWire
- 26 days ago - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Benzinga
- 5 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer - GlobeNewsWire
- 6 weeks ago - HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China - Seeking Alpha
- 6 weeks ago - HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China - Seeking Alpha
- 6 weeks ago - HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China - GlobeNewsWire
- 7 weeks ago - HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia - GlobeNewsWire